Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Source filing unavailable
Q4 2013 · —
Revenue$220.77M$220.77M+3.0% vs Q4 2012 Net Income$13.77M$13.77M+7.7% vs Q4 2012 EPS Diluted$0.45$0.45−2.2% vs Q4 2012 Gross Profit$136,932,000+3.3% Operating Incomederived$63,148,000+240.3% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Operating Cash Flowderived$11,696,000N/M Free Cash Flowderived$7,117,000N/M Margins · derivedGross margin62.0%+0.2 pt vs Q4 2012
Operating margin28.6%+19.9 pt vs Q4 2012
Net margin6.2%+0.3 pt vs Q4 2012